Saralasin (intravenous injection, 5-50 μg/kg, a single dose) ameliorates the oxidative stress and tissue injury in cerulein-induced pancreatitis[5].
Saralasin (subcutaneous injection, 10 and 30 mg/kg, a single dose) increases serum renin activity (SRA) in normal, conscious rats, without markedly altering blood pressure or heart rate[6].
| Animal Model: | Cerulein-induced acute pancreatitis rats model[5] |
| Dosage: | 5, 10, 20, and 50 μg/kg, a single dose. |
| Administration: | Intravenous injection |
| Result: | Restored the pancreatic morphological characteristics to the control level.
Reduced pancreatic injury and suppressed the glutathione depletion induced by cerulean.
|
| Animal Model: | Male Sprague-Dawley rats[6] |
| Dosage: | 10 and 30 mg/kg, a single dose. |
| Administration: | Subcutaneous injection |
| Result: | Stimulated renin release without altering blood pressure or heart rate at the time of measuring serum renin levels 20 minutes after injection. |
